About OMRF and Alexion
Chartered in 1946, OMRF (http://www.omrf.org) is a nonprofit biomedical research institute that focuses its research on cardiovascular disease, Alzheimer's, lupus and cancer. For more information, please contact Adam Cohen (adam- firstname.lastname@example.org) at the Oklahoma Medical Research Foundation, (405) 271-7159.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to
develop and deliver life-changing drug therapies for patients with serious
and life-threatening medical conditions. Alexion is engaged in the
discovery, development and commercialization of therapeutic products aimed
at treating patients with a wide array of severe disease states, including
hematologic diseases, cancer, and autoimmune disorders. Alexion is
evaluating other potential indications for Soliris as well as other
formulations of eculizumab for additional clinical indications, and is
pursuing development of other antibody product candidates in early stages
of development. This press release and further information about Alexion
Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.
Contact: Alexion Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
Makovsky & Company
Mark Marmur (Media)
|SOURCE Alexion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved